ClinicalTrials.gg
RecruitingNCT07660328Updated Oct 28, 2026

Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented With Carpal Tunnel Syndrome

An interventional study of Transfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR } and Standard Hand Rehabilitation [ US } in Carpal Tunnel Syndrome (CTS) Post-burn, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Carpal Tunnel Syndrome by Cairo University — 9 open to participants now, 10 under way, none of them phase 3. Carpal Tunnel Syndrome · Cairo University.

Planned enrollment
12th of 20
52 · median 55
Started
2026
with 1 other
No phase
19 of 21
9 open now
Registered
21st of 21
by date

Among the 21 studies in Carpal Tunnel Syndrome by Cairo University, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 with no phase, and was the 21st registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

9 of the 21 studies in Carpal Tunnel Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carpal Tunnel Syndrome by Cairo University, or all of them as a file.
02

Study summary

Carpal Tunnel Syndrome (CTS) is a common entrapment neuropathy that can develop as a secondary complication following deep burns involving the hand or wrist. Post-burn CTS arises due to factors such as fibrosis, edema, and scar contracture, which may increase pressure on the median nerve within the carpal tunnel, leading to significant pain, sensory disturbances, and impaired hand function Recent studies support the effectiveness of Transfer Energy Capacitive and Resistive (TECAR ) therapy in idiopathic CTS, showing improvements in pain, symptom severity, and function, as measured by validated tools such as the Boston Carpal Tunnel Questionnaire (BCTQ) and Visual Analogue Scale (VAS).

A study reported that both TECAR and ultrasound groups showed significant symptom improvement after treatment, although ultrasound had more sustained effects on median nerve cross-sectional area at 3 months

Read the detailed description

This study will involve 52 patients diagnosed with CTS post-burn; they will receive TECAR as an intervention. The outcome measures include ( VAS, Arabic version of Boston Carpal Tunnel Questionnaire, and Camry Digital Handgrip Dynamometer

03

Conditions studied

  • Carpal Tunnel Syndrome (CTS) Post-burn

Keywords

  • carpal tunnel syndrome post-burn
  • TECAR
  • Hand grip
  • BOSTON questionnaire
  • VAS
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is between 20 and 40 years of age.
  • Diagnosed with mild to moderate carpal tunnel syndrome (CTS).
  • History of an upper limb burn, with the percentage of the Total Body Surface Area (TBSA) ranging from 20% to 25%.
  • Upper limb burn is diagnosed as a 2nd or 3rd-degree burn complicated with carpal tunnel syndrome.
  • Carpal tunnel syndrome diagnosis is clinically confirmed using physical examination, including a positive Tinel's sign and positive Phalen's test.
  • Participant provides written before enrollment.

Exclusion criteria

Exclusion Criteria:

  • History of double crush syndrome, cervical radiculopathy, or fibromyalgia.
  • History of wrist fracture or distal radius fracture.
  • Diagnosis of systemic or local diseases that contribute to peripheral neuropathy, including Diabetes Mellitus or rheumatoid arthritis (RA).
  • Diagnosis of hypothyroidism, skin diseases, or peripheral vascular diseases.
  • Current or past history of cancer.
  • Use of a hand or wrist splint within the past three months.
  • Presence of an implanted pacemaker or electrical prosthesis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    The TECAR Group

    Participants in this group will receive TECAR therapy at a frequency of 0.5 MHz and intensity of 30 to 50% and medium Capacitive Energy Transfer electrode (60 mm), 5 min capacitive (CAP) and 10 min resistive (RES), three sessions per week for two weeks plus standard post-burn hand rehabilitation

    Device: Transfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR } · Other: Standard Hand Rehabilitation [ US }

  • Active comparator
    The Control Group

    Participants in this arm will receive standard post-burn hand rehabilitation (e.g., Exercise, stretch, and US)

    Other: Standard Hand Rehabilitation [ US }

Interventions

  • DeviceTransfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR }

    TECAR therapy at a frequency of 0.5 MHz and intensity of 30 to 50% and medium Capacitive Energy Transfer electrode (60 mm), 5 min capacitive (CAP) and 10 min resistive (RES), The passive electrode was fixed to the dorsum of the hand while the active electrode was moved in a circular manner from the proximal carpal tunnel to the median nerve pathway of the palm in three sessions per week for two weeks

  • OtherStandard Hand Rehabilitation [ US }

    US using a 3 MHz probe at a dose of 1.5 watts/cm2 for 5 min intermittently for 2 weeks, 5 times a week, plus mobility and strengthening exercises

06

What researchers measure

Primary outcomes

  1. Symptom Severity

    The Arabic version of the BCTQ-SSS will be used to self-report symptom severity. It consists of 11 items assessing pain, numbness, paresthesia, weakness, and nocturnal symptoms. Each item is scored from 1 (never/none) to 5 (most severe). The overall score is calculated as the mean of the items, ranging from 1 to 5, where higher scores indicate worse symptom severity.

    Time frame: Baseline and 2 weeks

  2. Functional Status

    The Arabic version of the BCTQ-FSS will be used to evaluate hand function across 8 common activities. Each activity is scored from 1 (no difficulty) to 5 (cannot perform the activity at all). The total score is the mean of the items, ranging from 1 to 5, where higher scores represent greater functional impairment.

    Time frame: Baseline and 2 weeks.

  3. Grip Strength

    Objective hand function and force production of the median nerve-innervated muscles will be measured using a Camry Digital Handgrip Dynamometer. Measurements are recorded in kilograms (kg), up to a maximum strength of 90 kg. Higher scores indicate greater hand grip strength.

    Time frame: Baseline and 2 weeks.

Secondary outcomes

  1. Pain Intensity

    Pain intensity will be measured using the Arabic version of the VAS, where patients mark their current pain level on a 10-cm line. The scale ranges from 0 cm ("no pain") to 10 cm ("worst pain"). Higher scores represent greater pain severity.

    Time frame: Baseline and 2 weeks.

07

Study locations

1 of 1 sites recruiting
  • QWAM physio clinic
    Al Mansurah, Mansoura 35511, Egypt
    Recruiting
08

References and documents

Publications

  • Yeste-Fabregat M, Baraja-Vegas L, Vicente-Mampel J, Perez-Bermejo M, Bautista Gonzalez IJ, Barrios C. Acute Effects of Tecar Therapy on Skin Temperature, Ankle Mobility and Hyperalgesia in Myofascial Pain Syndrome in Professional Basketball Players: A Pilot Study. Int J Environ Res Public Health. 2021 Aug 19;18(16):8756. doi: 10.3390/ijerph18168756. PubMed 34444508 ↗
  • Vahdatpour, B., Ghasemi, H. R., & Taheri, P. (2023). Effectiveness of TECAR Therapy on Clinical Symptoms and Neurophysiological Parameters of Patients with Carpal Tunnel Syndrome: A Randomized Clinical Trial. Middle East Journal of Rehabilitation and Health Studies, 10(3). https://doi.org/10.5812/mejrh-134171
  • Tezen O, Bilir EE, Uzun O, Yaniktas D, Senturk B, Yasar E. Evaluation of the efficacy of transfer energy capacitive and resistive therapy in patients with knee osteoarthritis. Turk J Med Sci. 2024 Oct 7;54(6):1302-1309. doi: 10.55730/1300-0144.5913. eCollection 2024. PubMed 39734340 ↗
  • Tashiro Y, Hasegawa S, Yokota Y, Nishiguchi S, Fukutani N, Shirooka H, Tasaka S, Matsushita T, Matsubara K, Nakayama Y, Sonoda T, Tsuboyama T, Aoyama T. Effect of Capacitive and Resistive electric transfer on haemoglobin saturation and tissue temperature. Int J Hyperthermia. 2017 Sep;33(6):696-702. doi: 10.1080/02656736.2017.1289252. Epub 2017 Feb 19. PubMed 28139939 ↗
  • Tezen O, Ata AM, Uzun O, Cakir F, Yasar E. Comparison of the effectiveness of ultrasound and transfer energy capacitive and resistive (TECAR) therapy in patients with carpal tunnel syndrome. Lasers Med Sci. 2025 Mar 19;40(1):147. doi: 10.1007/s10103-025-04412-z. PubMed 40106005 ↗
  • Szabo DA, Neagu N, Teodorescu S, Predescu C, Sopa IS, Panait L. TECAR Therapy Associated with High-Intensity Laser Therapy (Hilt) and Manual Therapy in the Treatment of Muscle Disorders: A Literature Review on the Theorised Effects Supporting Their Use. J Clin Med. 2022 Oct 19;11(20):6149. doi: 10.3390/jcm11206149. PubMed 36294470 ↗
  • Rosario NB, De Jesus O. Electrodiagnostic Evaluation of Carpal Tunnel Syndrome. 2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK562235/ PubMed 32965906 ↗
  • Ribeiro, S., Henriques, B., & Cardoso, R. (2018). To cite this article Samuel Ribeiro, Bebiana Henriques, Ricardo Cardoso. The Effectiveness of Tecar Therapy in Musculoskeletal Disorders. In International Journal of Public Health and Health Systems (Vol. 3, Issue 5). http://www.openscienceonline.com/journal/ijphhs
  • Niajalili M, Mohsen Roostayi M, Daryabor A, Naimi SS, Amoli MJ. The effect of Tecar therapy on neurological disorders and nerve conduction velocity of lower limbs in peripheral neuropathy of type 2 diabetic patients: A six-week follow-up study. Turk J Phys Med Rehabil. 2023 Oct 12;69(4):479-487. doi: 10.5606/tftrd.2023.11875. eCollection 2023 Dec. PubMed 38766579 ↗
  • Mitie Ida, A., Borba Neves, E., & Wan Stadnik, A. M. (2023). Effects of Tecartherapy on Body Tissue: A Systematic Review. Journal of Biomedical Science and Engineering, 16(10), 133-148. https://doi.org/10.4236/jbise.2023.1610010
  • Mahran, H. G., Mohammed, A. H., & Aboelazm, S. N. (2015). EXTRACORPOREAL SHOCKWAVE THERAPY FOR POST BURN CARPAL TUNNEL SYNDROME. International Journal of Physiotherapy and Research, 3(2), 938-946. https://doi.org/10.16965/ijpr.2015.111
  • Lupton-Smith A, Fourie K, Mazinyo A, Mokone M, Nxaba S, Morrow B. Measurement of hand grip strength: A cross-sectional study of two dynamometry devices. S Afr J Physiother. 2022 Sep 26;78(1):1768. doi: 10.4102/sajp.v78i1.1768. eCollection 2022. PubMed 36262213 ↗
  • Lupowitz LG, Ramus L, Delacour F, Johnson K. TECAR Therapy: A Clinical Commentary on its Evolution, Application, and Future in Rehabilitation. Int J Sports Phys Ther. 2025 Apr 1;20(4):632-640. doi: 10.26603/001c.130909. eCollection 2025. PubMed 40182911 ↗
  • Diagne, N., Tonga, M., Seye, M., Sy, A., Mboup, D., Guèye, A., Sakho, M., Lo, P., Seck, L., Fall, M., Ndiaye, M., & Diop, A. (2024). Grip Strength and Carpal Tunnel: What Interest in Management. Journal of Physical Medicine, 5(1). https://doi.org/10.36959/942/347
  • Chesterton LS, Blagojevic-Bucknall M, Burton C, Dziedzic KS, Davenport G, Jowett SM, Myers HL, Oppong R, Rathod-Mistry T, van der Windt DA, Hay EM, Roddy E. The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial. Lancet. 2018 Oct 20;392(10156):1423-1433. doi: 10.1016/S0140-6736(18)31572-1. PubMed 30343858 ↗
  • Cao, J., Jia, T., Lao, J., Liu, A., & Rui, J. (2022). Evaluation of different physical examination methods for the diagnosis of carpal tunnel syndrome. World Academy of Sciences Journal, 4(5), 33. https://doi.org/10.3892/wasj.2022.168
  • Alanazy MH. Clinical and electrophysiological evaluation of carpal tunnel syndrome: approach and pitfalls. Neurosciences (Riyadh). 2017 Jul;22(3):169-180. doi: 10.17712/nsj.2017.3.20160638. PubMed 28678210 ↗
  • Albert T, Perrot P, Lecoq FA, Lancien U. Post-burn carpal tunnel syndrome: A systematic review. Hand Surg Rehabil. 2025 Jun;44(3):102134. doi: 10.1016/j.hansur.2025.102134. Epub 2025 Mar 22. PubMed 40127842 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 2 months is below that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Aug 9, 2026was Jun 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
QWAM physio clinic is now Recruiting
Oct 28, 2026
Start date
Jun 16, 2026→Aug 9, 2026 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    QWAM physio clinic is now Recruiting
    Start date Jun 16, 2026→Aug 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07660328
Lead sponsor
Cairo University
Responsible party
Ahmed Abdelnaser Mohamed Mohamed Youness (Demonstrator of Surgery Department, Faculty of Physical Therapy, Cairo University) — Principal investigator
First posted
Jun 22, 2026
Start date
Aug 9, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 28, 2026

Study contacts

Ahmed abdelnasr Mohamed Youness, Demonstrator (TA)
Contact
pt.ahmed.mido@gmail.com
+2001553712231
Nada Mohamed Yousef, Lecturer
Contact
Dr.nada123.ny@gmail.com
+2001002010168
Wafaa Hussien Borhan, Professor
study director · Cairo University
Ashraf Alsibai Mohamed, Professor
study director · Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion